Donepezil
- Generic Name
- Donepezil
- Brand Names
- Adlarity, Aricept, Namzaric
- Drug Type
- Small Molecule
- Chemical Formula
- C24H29NO3
- CAS Number
- 120014-06-4
- Unique Ingredient Identifier
- 8SSC91326P
- Background
In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other ty...
- Indication
Donepezil, administered orally or via transdermal delivery system, is indicated for the treatment of dementia of the Alzheimer's type. It is also available as an extended-release capsule in combination with memantine for the treatment of moderate-to-severe dementia of the Alzheimer's type in patients previously stabilized on 10mg of donepezil hydrochloride o...
- Associated Conditions
- Alzheimer's Disease (AD), Dementia With Lewy Body Disease, Dementia due to Parkinson's disease, Dementia of the Alzheimer's Type, Vascular Dementia (VaD), Moderate Alzheimer's Type Dementia, Severe Alzheimer's Type Dementia
- Associated Therapies
- -
Effects of Cholinergic Augmentation on Measures of Balance and Gait
- First Posted Date
- 2014-08-01
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 49
- Registration Number
- NCT02206620
- Locations
- 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States
A Phase I Clinical Study, Randomized, Single-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects.
- First Posted Date
- 2014-06-30
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- Icure Pharmaceutical Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02178124
- Locations
- 🇰🇷
ASAN Medical Center, Seoul, Korea, Republic of
Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice
- First Posted Date
- 2014-06-12
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 8662
- Registration Number
- NCT02162264
Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease
- First Posted Date
- 2014-06-12
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 3482
- Registration Number
- NCT02162251
A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients
- First Posted Date
- 2014-06-09
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Eisai Korea Inc.
- Target Recruit Count
- 2231
- Registration Number
- NCT02158910
Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 36
- Registration Number
- NCT02064920
A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil
- Conditions
- Interventions
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 195
- Registration Number
- NCT02055703
- Locations
- 🇺🇸
WCT Early Development, San Antonio, Texas, United States
Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2014-01-31
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT02051335
Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly
- Conditions
- Interventions
- First Posted Date
- 2013-09-26
- Last Posted Date
- 2020-07-13
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 121
- Registration Number
- NCT01951118
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Bioavailability Study of Donepezil Hydrochloride Tablets 23 mg Under Fed Condition
- First Posted Date
- 2013-08-15
- Last Posted Date
- 2013-08-15
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 94
- Registration Number
- NCT01923259
- Locations
- 🇨🇦
Algorithme Pharma Inc., Mount Royal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.